CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 49 enrolled
Drug / intervention
Human Normal Immunoglobulin for Subcutaneous Administrationbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00419341
NCT00419341Phase 3Completed
CompareCT.gov

A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)

CSL Behring·interventional·Posted Jan 8, 2007·Updated Jan 25, 2013

In Brief

A Phase 3 clinical trial evaluating Human Normal Immunoglobulin for Subcutaneous Administration for Primary Immune Deficiency. Completed, enrolled 49 participants across 13 sites.

Detailed Summary

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Immune Deficiency
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 8, 2007
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.5 years ago

Interventions

Human Normal Immunoglobulin for Subcutaneous Administrationbiological